{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:56:27Z","timestamp":1648515387739},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1007\/s11899-007-0015-1","type":"journal-article","created":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T10:12:52Z","timestamp":1177927972000},"page":"104-110","source":"Crossref","is-referenced-by-count":0,"title":["What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?"],"prefix":"10.1007","volume":"2","author":[{"given":"Istv\u00e1n","family":"Moln\u00e1r","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bayard L.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,1]]},"reference":[{"key":"15_CR1","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","volume":"240","author":"N. Zein","year":"1988","unstructured":"Zein N, Sinha AM, McGahren WJ, Ellestad GA: Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988, 240:1198\u20131201.","journal-title":"Science"},{"key":"15_CR2","first-page":"1490","volume":"7","author":"P.F. Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001, 7:1490\u20131496.","journal-title":"Clin Cancer Res"},{"key":"15_CR3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","volume":"18","author":"V.H.J. Velden van der","year":"2004","unstructured":"van der Velden VHJ, Boeckx N, Jedema I, et al.: High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg\u00ae) treatment in acute myeloid leukemia patients. Leukemia 2004, 18:983\u2013988.","journal-title":"Leukemia"},{"key":"15_CR4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U","volume":"118","author":"I. Jilani","year":"2002","unstructured":"Jilani I, Estey E, Huh Y, et al.: Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002, 118:560\u2013566.","journal-title":"Am J Clin Pathol"},{"key":"15_CR5","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/sj.leu.2403901","volume":"19","author":"S. Amadori","year":"2005","unstructured":"Amadori S, Suciu S, Stasi R, et al.: Gemtuzumab ozogamicin (Mylotarg\u00ae) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell\u2019Adulto Leukemia Groups. Leukemia 2005, 19:1768\u20131773.","journal-title":"Leukemia"},{"key":"15_CR6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.leu.2403205","volume":"18","author":"I. Jedema","year":"2004","unstructured":"Jedema I, Barge RMY, van der Velden VHJ, et al.: Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004, 18:316\u2013325.","journal-title":"Leukemia"},{"key":"15_CR7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1592\/phco.21.15.1175.33890","volume":"21","author":"J.M. Korth-Bradley","year":"2001","unstructured":"Korth-Bradley JM, Dowell JA, King SP, et al: Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy 2001, 21:1175\u20131180.","journal-title":"Pharmacotherapy"},{"key":"15_CR8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0091270004267595","volume":"44","author":"M. Buckwalter","year":"2004","unstructured":"Buckwalter M, Dowell JA, Korth-Bradley J, et al.: Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol 2004, 44:873\u2013880.","journal-title":"J Clin Pharmacol"},{"key":"15_CR9","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","volume":"93","author":"E.L. Sievers","year":"1999","unstructured":"Sievers EL, Appelbaum FR, Spielberger RT, et al.: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999, 93:3678\u20133684.","journal-title":"Blood"},{"key":"15_CR10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","volume":"106","author":"R.J. Arceci","year":"2005","unstructured":"Arceci RJ, Sande J, Lange B, et al.: Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33(+) acute myeloid leukemia. Blood 2005, 106:1183\u20131188.","journal-title":"Blood"},{"key":"15_CR11","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"R.A. Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmauer EA, et al.: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104:1442\u20131452.","journal-title":"Cancer"},{"key":"15_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.leukres.2004.04.011","volume":"29","author":"C. Nabhan","year":"2005","unstructured":"Nabhan C, Rundhaugen LM, Riley MB, et al.: Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res 2005, 29:53\u201357.","journal-title":"Leuk Res"},{"key":"15_CR13","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1182\/blood.V99.12.4343","volume":"99","author":"E.H. Estey","year":"2002","unstructured":"Estey EH, Thall PF, Giles FJ, et al.: Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002, 99:4343\u20134349.","journal-title":"Blood"},{"key":"15_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1532\/IJH97.05069","volume":"82","author":"A. Takeshita","year":"2005","unstructured":"Takeshita A, Shinjo K, Naito K, et al.: Two patients with all- trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent. Int J Hematol 2005, 82:445\u2013448.","journal-title":"Int J Hematol"},{"key":"15_CR15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2141.2001.03091.x","volume":"115","author":"M.C. Petti","year":"2001","unstructured":"Petti MC, Pinazzi MB, Diverio D, et al.: Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg\u2122 CMA-676). Br J Haematol 2001, 115:63\u201365.","journal-title":"Br J Haematol"},{"key":"15_CR16","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","volume":"104","author":"F. Lo-Coco","year":"2004","unstructured":"Lo-Coco F, Cimino G, Breccia M, et al.: Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004, 104:1995\u20131999.","journal-title":"Blood"},{"key":"15_CR17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.thj.6200367","volume":"5","author":"J. Schwarz","year":"2004","unstructured":"Schwarz J, Markova J, Pekova S, et al.: A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia. Hematol J 2004, 5:279\u2013280.","journal-title":"Hematol J"},{"key":"15_CR18","doi-asserted-by":"crossref","unstructured":"Zwaan CM, Reinhardt D, Zimmermann M, et al.: A phase II study of single-agent gemtuzumab ozogamicin in relapsed\/refractory pediatric acute myeloid leukemia (AML) [abstract]. J Clin Oncol 2005 ASCO Annual Meeting Proceedings, 23(June 1 suppl):Abstract 8524.","DOI":"10.1200\/jco.2005.23.16_suppl.8524"},{"key":"15_CR19","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/1042819042000219485","volume":"45","author":"P.P. Piccaluga","year":"2004","unstructured":"Piccaluga PP, Martinelli G, Rondoni M, et al.: Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 2004, 45:1791\u20131795.","journal-title":"Leuk Lymphoma"},{"issue":"suppl2","key":"15_CR20","first-page":"S376","volume":"35","author":"J. Cornillon","year":"2005","unstructured":"Cornillon J, Peoc\u2019h M, Jaubert J, et al.: Gemtuzumab ozogamicin as therapy for localised cutaneaous granulocytic sarcoma after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005, 35(suppl 2):S376\u2013S377.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR21","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1080\/1042819021000016078","volume":"43","author":"G.J. Roboz","year":"2002","unstructured":"Roboz GJ, Knovich MA, Bayer RL, et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma 2002, 43:1951\u20131955.","journal-title":"Leuk Lymphoma"},{"key":"15_CR22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-0609.2004.00321.x","volume":"73","author":"R. Swords","year":"2004","unstructured":"Swords R, Hayden PJ, Molloy K, et al.: Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT. Eur J Haematol 2004, 73:450\u2013451.","journal-title":"Eur J Haematol"},{"key":"15_CR23","doi-asserted-by":"crossref","unstructured":"Raj K, Aldouri M, Ho A, et al.: Gemtuzumab ozogamicin with donor leucocyte infusions is safe and effective therapy for a subgroup of relapsed acute myeloid leukaemia and myelodysplastic syndrome following allogeneic haemopoietic stem cell transplantation (HSCT) [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 1806.","DOI":"10.1182\/blood.V104.11.1806.1806"},{"key":"15_CR24","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1345\/aph.1C511","volume":"37","author":"F.J. Giles","year":"2003","unstructured":"Giles FJ, Cortes JE, Halliburton TA, et al.: Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother 2003, 37:1182\u20131185.","journal-title":"Ann Pharmacother"},{"key":"15_CR25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/annonc\/mdh324","volume":"15","author":"C. Nabhan","year":"2004","unstructured":"Nabhan C, Rundhaugen L, Jatoi M, et al.: Gemtuzumab ozogamicin (Mylotarg\u2122) is infrequently associated with sinusoidal obstructive syndrome\/veno-occlusive disease. Ann Oncol 2004, 15:1231\u20131236.","journal-title":"Ann Oncol"},{"key":"15_CR26","unstructured":"Erba HP, Stadtmauer EA, Larson RA, et al.: Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg\u00ae) with or without hematopoietic stem cell transplantation [abstract]. Blood (ASH Annual Meeting Abstracts) 2003, 102:Abstract 3241."},{"key":"15_CR27","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M. Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, et al.: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003, 102:1578\u20131582.","journal-title":"Blood"},{"key":"15_CR28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1365-2141.2003.04667.x","volume":"123","author":"A. Saviola","year":"2003","unstructured":"Saviola A, Luppi M, Potenza L, et al.: Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide. Br J Haematol 2003, 123:752\u2013753.","journal-title":"Br J Haematol"},{"key":"15_CR29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2710.2006.00742.x","volume":"31","author":"D. Lannoy","year":"2006","unstructured":"Lannoy D, Decaudin B, de Laguerenne AG, et al.: Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report. J Clin Pharm Ther 2006, 31:389\u2013392.","journal-title":"J Clin Pharm Ther"},{"key":"15_CR30","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2003-10-3612","volume":"103","author":"B. Versluys","year":"2004","unstructured":"Versluys B, Bhattacharaya R, Steward C, et al.: Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure [letter]. Blood 2004, 103:1968.","journal-title":"Blood"},{"key":"15_CR31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00277-006-0103-7","volume":"85","author":"C. Romani","year":"2006","unstructured":"Romani C, Murru R, Adamo F, et al.: Sensorimotor peripheral neuropathy in an elderly AML patient in complete remission while receiving gemtuzumab ozogamicin as maintenance therapy. Ann Hematol 2006, 85:411\u2013412.","journal-title":"Ann Hematol"},{"key":"15_CR32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ajh.20432","volume":"80","author":"M. Kurt","year":"2005","unstructured":"Kurt M, Shorbagi A, Altundag K, et al.: Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia. Am J Hematol 2005, 80:213\u2013215.","journal-title":"Am J Hematol"},{"key":"15_CR33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704886","volume":"35","author":"T.S. Lin","year":"2005","unstructured":"Lin TS, Penza SL, Avalos BR, et al.: Diffuse alveolar hemorrhage following gemtuzumab ozogamicin. Bone Marrow Transplant 2005, 35:823\u2013824.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR34","doi-asserted-by":"crossref","unstructured":"Baccarani M, Durrant S, Linkesh W, et al.: Preliminary report of a phase 2 study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg\u00ae) given in combination with cytarabine in patients with acute myeloid leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2002, 100:Abstract 341.","DOI":"10.3816\/CLM.2002.s.005"},{"key":"15_CR35","unstructured":"Allen LF: Mylotarg\u00ae (gemtuzumab ozogamicin). Presentation to FDA Oncologic Drugs Advisory Committee, November 8, 2005."},{"key":"15_CR36","doi-asserted-by":"crossref","unstructured":"Roboz GJ, Ritchie EK, Schuster MW, et al.: Gemtuzumab ozogamicin is an acceptable alternative to anthracyclines in combination with standard dose infusional cytarabine as induction therapy for elderly patients with acute myeloid leukemia (AML) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1856.","DOI":"10.1182\/blood.V106.11.1856.1856"},{"key":"15_CR37","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","volume":"102","author":"W.J. Kell","year":"2003","unstructured":"Kell WJ, Burnett AK, Chopra R, et al.: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003, 102:4277\u20134283.","journal-title":"Blood"},{"key":"15_CR38","doi-asserted-by":"crossref","unstructured":"Stone RM, Moser B, Schulman P, et al.: A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients (pts) with refractory or relapsed acute myeloid leukemia (AML): CALGB 19902 [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 873.","DOI":"10.1182\/blood.V104.11.873.873"},{"key":"15_CR39","unstructured":"De Angelo DJ, Stone RM, Durrant S, et al.: Gemtuzumab ozogamicin (Mylotarg\u00ae) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: Two age-specific phase 2 trials [abstract]. Blood (ASH Annual Meeting Abstracts) 2003, 102:Abstract 341."},{"key":"15_CR40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0145-2126(03)00022-5","volume":"27","author":"A. Tsimberidou","year":"2003","unstructured":"Tsimberidou A, Cortes J, Thomas D, et al.: Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003, 27:893\u2013897.","journal-title":"Leuk Res"},{"key":"15_CR41","doi-asserted-by":"crossref","unstructured":"Langston AA, McMillan S, Lonial S, et al.: A phase I trial of ara-C, topotecan, and gemtuzumab ozogamicin (Mylotarg\u00ae) for advanced MDS and secondary or relapsed AML [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 1814.","DOI":"10.1182\/blood.V104.11.1814.1814"},{"key":"15_CR42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-002-0539-y","volume":"50","author":"J. Cortes","year":"2002","unstructured":"Cortes J, Tsimberidou AM, Alvarez R, et al.: Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 2002, 50:497\u2013500.","journal-title":"Cancer Chemother Pharmacol"},{"key":"15_CR43","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.leukres.2005.02.005","volume":"29","author":"P. Chevallier","year":"2005","unstructured":"Chevallier P, Roland V, Mahe B, et al.: Administration of Mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2005, 29:1003\u20131007.","journal-title":"Leuk Res"},{"key":"15_CR44","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0145-2126(03)00021-3","volume":"27","author":"E. Apostolidou","year":"2003","unstructured":"Apostolidou E, Cortes J, Tsimberidou A, et al.: Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003, 27:887\u2013891.","journal-title":"Leuk Res"},{"key":"15_CR45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00280-002-0546-z","volume":"51","author":"Y. Alvarado","year":"2003","unstructured":"Alvarado Y, Tsimberidou A, Kantarjian H, et al.: Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003, 51:87\u201390.","journal-title":"Cancer Chemother Pharmacol"},{"key":"15_CR46","first-page":"950","volume":"89","author":"S. Amadori","year":"2004","unstructured":"Amadori S, Suciu S, Willemze R, et al.: Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004, 89:950\u2013956.","journal-title":"Haematologica"},{"key":"15_CR47","unstructured":"Jiang YX, Kantarjian HM, Faderl SH, et al.: Follow-up of gemtuzumab ozogamycin (Mylotarg) and all- trans retinoic acid in untreated acute promyelocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2003, 102:Abstract 2284."},{"key":"15_CR48","doi-asserted-by":"crossref","first-page":"7164S","DOI":"10.1158\/1078-0432.CCR-1004-0018","volume":"11","author":"E. Roman","year":"2005","unstructured":"Roman E, Cooney E, Harrison L, et al.: Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 2005, 11:7164S\u20137170S.","journal-title":"Clin Cancer Res"},{"key":"15_CR49","doi-asserted-by":"crossref","unstructured":"de Lima M, Giralt S, Caldera Z, et al.: Results of a phase I\/II study of gemtuzumab ozogamicin added to fludarabine (F), melphalan (M) and allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed myeloid leukemias [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 841.","DOI":"10.1182\/blood.V106.11.841.841"},{"key":"15_CR50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbmt.2004.12.187","volume":"11","author":"H.F. Fernandez","year":"2005","unstructured":"Fernandez HF, Kim HT, Bennett JM, et al.: Gemtuzumabozogamicin (GO, Mylotarg\u00ae) as part of consolidation therapy for AML before autograft: low incidence of hepatic veno-occlusive disease. Biol Blood Marrow Transplant 2005, 11:62\u201363.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0015-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-007-0015-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0015-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T15:56:31Z","timestamp":1587484591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-007-0015-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1007\/s11899-007-0015-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}